Excitingly, the company recently received approval to complete it's first-in human test of RGSH4K, a vaccine designed to activate the immune system to fight against cancer cells. Trial in canines of this vaccine have shown promising results. Benefits of cancer immunotherapies such as this include avoiding side effects of chemotherapy.
The company has also received approval to commence trials of their stem cell treatment "Progenza". These step cells will be injected into the patients knee to reduce the effects of Arthritis.
The stock has attracted bullish targets from Analysts/newsletters including:
For further in depth information regarding the stock I recommend clicking on the above links to view the research.
Technically today was a significant day for the stock. It closed above a triple top of $0.18 (see chart today) on a spike in volumes both today and yesterday.
Investing in Biotech companies is high risk. Failures of trials can lead to significant share price destruction.